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   Breast Cancer is one of common types of cancer in the world and is considered one of the causes of 
death among Iraqi women . The discovery of the hormone receptors (estrogen and progesterone) a 
significant impact in the selection of patients for treatment and expected to live after period and to the 
possibility of recurrence treatment again is because the relationship between tumor grade and the 
percentage of representation of hormone receptors on the surface cells . The research based on measuring 
the proportion of ER and PR in tissue and blood serum and note relationship between the level of 
receptors and the clinical situation in Iraqi women with breast cancer . The study has been started from 
May 2014 to December 2014 in the Educational Tumor Hospital were selected infected women in the age 
group (28-68) years as measured by the proportion of their ER and PR in tissue and serum .The results 
showed that the proportion of women  with a family history of patients is 62.5% and that the patients 
whose ratio to have a tumor of the second degree is 76.7% and the third degree was 13.3% and that the 
first degree ratio is 10% and that there is no significant difference in the measurement of the percentage 
ER and PR in ELISA technique and Immunohistochemistry . Sensitivity and Specifity of 
Immunohistochemistry study is better than ELISA technique because the value of IHC sensitivity and 
specifity for  ER and PR are 70%(1.0)ng/ml and 69%(1.0)ng/ml respectively while in ELISA technique 
are 38%(0.9)ng/ml and 20%(0.95)ng/ml respectively .                                    
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Introduction :  
   Breast Cancer is the most common cancer in women . Worldwide , more than one million women are 
affected by this disease every year . In Iraq it constituted 19.59% total cancer cases and alone is accounted 
for 31% of all new cancer cases among females in Iraq (AL-Khafaji and etal 2014). It is now firmly 
believed that breast cancer commonly starts in the epithelium which lines the terminal ductules within the 
lobule . Physiologically , the human female breast is under the primary control of different hormones like 
sex steroid hormones which play a significant role in the physiology of the human breast (Hana 2010; 
Saeed and Majeed 2011) . Number of tumor associated with hormones and its receptors which has been 
evaluated for monitoring or detecting breast cancer . Estrogen and Progesterone receptors have been 
found in normal and malignant tissue (AL-Atrooshi 2014 ; AL-Siagh and etal 2012) . Estrogen and 
Progesterone and them receptors play an important roles in the risk factors for breast cancer (Hayashi 
and etal 2003 ; Lim and etal 2014) .The estrogen and progesterone receptors belong to a super-family of 
nuclear hormone receptors . These receptor proteins function as transcription factors when they are 
bound to their respective ligands ; these receptors share a common structural and functional organization 
(AL-Atrooshi 2014) .                             
Aim of the study : 
Our study can be categorized into these point: 
(1)Evaluation of IHC markers (ER,PR and Her-2/neu) in Iraqi breast cancer women. 
(2)Estimation of serum ER and PR by ELISA kit . 
(3)Clinicopathological finding correlated between hormone receptors and Estimation the sensitivity and 
specifity of IHC and ELISA . 
 
Patients and Methods : 
Patient: 
   From May 2014 to December 2014 , 64 patients were newly diagnosed as breast cancer with 
chemotherapy treatment were included in this study . The patients were diagnosed at Educational Tumor 
Hospital . Blood samples were collected from the 64 patients to estimate ER and PR . The main data and 
parameter include in our study : patientꞌs age, family history of breast cancer and another cancer, and 
pattern of menstrual cycle.                                                                                                        
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   Twenty patients (women) diagnosed as having breast cancer were also included in this study as a control 
group .                                                                                           
 
Samples Collection :  
Blood Sampling : 
   Three to five ml of blood was collected from 64 patients and from twenty control individuals . Blood 
samples were drawn from cubital vein . Blood samples were centrifuged at 3000 rpm for 2-5 minutes then 
serum was separated and stored immediately . Specimen held for longer time by frozen at -20°C prior to 
assay .       
 
Methods: 
Immunohistochemistry for ER ,PR and Her-2/neu : 
   The Data of Immunohistochemistry for ER ,PR and Her-2/neu were obtained from patientꞌs reports .                                          
 
Estimation of serum ER and PR (Biochemical) :  
    Serum level of ER and PR were determined by Elabscience ELISA kit is an in vitro enzyme linked 
immunosorbent assay for quantitative measurment .                             
 
Statistical analysis : 
   Database was examined for errors by using Statistical Analysis System Programe – SAS (2012) in 
statistical analysis to study Clinicopathological analysis in breast cancer patients , and correlation between 
clinicopathological assessment and IHC tumor markers ER and PR , and correlation between sensitivity 
and specifity by IHC and ELISA in 64 patients with breast cancer (SAS 2012) .                                                    
  
Results and Discussion : 
Clinicopathological analysis : 
   Total group studied was in the age category of (28-68) years accounting for 64 patients . In this study 
table (1) show 63% of patients had apositive family history weather 77% it is second degree and 43% 
positive HER2 that agree with Numerous studies which suggest a strong link between the female hormone 
and the development of breast cancer (AL-Khafaji and etal 2014).                                                 
 
Table (1) : Clinicopathological analysis in breast cancer patients 
Clinicopathological analysis 
Percentage Number Age group/year(female) 
57.8 37 <=45 
42.2 27 >=45 
Percentage Number Family history 
37.5 24 None 
62.5 40 Positive 
100.0 64 Total 
Percentage Number T 
26.6 17 1.00 
62.5 40 2.00 
4.7 3 3.00 
6.3 4 4.00 
100.0 64 Total 
Percentage Number N 
1.6 1 0.00 
28.1 18 1.00 
57.8 37 2.00 
10.9 7 3.00 
1.6 1 4.00 
100.0 64 Total 
Percentage Number Grade 
10.0 6 1.00 
76.7 46 2.00 
13.3 8 3.00 
100.0 60 Total 
Percentage Number HER2 
34.5 20 -ve 
20.7 12 + 
1.7 1 ++ 
43.1 25 +++ 
100.0 58 Total 
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Correlation between immunohistochemical Analysis and ELISA ER and PR :  
   Table (2) show the value of ER ELISA was P<0.05 while PR ELISA was non significant and both ER 
IHC and PR IHC were non significant so this the first study to investigate the role of ER and PR on the 
risk of breast cancer in Iraqi postmonopausal women which agree with Lim and etal 2014 .                                        
 
Table (2) : Correlation between clinicopathological assessment and IHCtumor markers ER and PR 
Clinico-pathological analysis 
P-Value Mean+Std.D. Number Age at diagnosis 
P<0.01 45.2969+1.2075 64 patient 
P<0.01 37.4500+1.5735 20 control 
P-Value Mean+Std.D. Number ER ELISA 
P<0.05 0.5397+0.0772 64 patient 
P<0.05 0.2100+0.0478 20 control 
P-Value Mean+Std.D. Number PR ELISA 
NS 0.5175+0.0760 64 patient 
NS 0.2960+0.06647 20 control 
P-Value Mean+Std.D. Number ER IHC 
NS 0.4165+0.1113 17 -ve 
NS 0.6590+0.1880 21 + 
NS 0.5125+0.1402 8 ++ 
NS 0.5218+0.1548 11 +++ 
NS 0.5396+0.0840 57 Total 
P-Value Mean+Std.D. Number PR IHC 
NS 0.4568+0.1134 19 -ve 
NS 0.6680+0.1550 25 + 
NS 0.3175+0.1627 4 ++ 
NS 0.4538+0.1380 13 +++ 
NS 0.5336+0.0791 61 Total 
  
  
Correlation between sensitivity and specifity by IHC and ELISA : 
   Table (3) show that the sensitivity of ER IHC and PR IHC were 70% and 69% respectively while the 
sensitivity of ER ELISA and PR ELISA were 38% and 20% respectively and the specifity of both ER IHC 
and PR IHC were 1.00 ng/ml and the specifity of ER ELISA was 0.90 ng/ml while PR ELISA was 0.95 
ng/ml . Our results show the IHC technique was better than ELISA. And the ER cutoff was 0.6912 ng/ml 
while PR cutoff was 0.89056 ng/ml which disagreement with Sun and etal 2001.       
 
Table (3) : Correlation between sensitivity and specifity by IHC and ELISA in 64 patients with breast 
cancer  
PR ELISA ER ELISA PR IHC ER IHC Parameters 
20% 38% 69% 70% sensitivity 
0.95 0.90 1.00 1.00 Specifity ng/ml 
 
References : 
(1)AL-Atrooshi,S.A.M. (2014) .Immunohistochemical Expression of Estrogen and Progesterone Receptors 
in human colorectal carcinoma (clinicopathological study) .J.Fac.Med.Baghdad,Vol.56,No.3,pp:296-300.                                                                      
(2)AL-Khafaji ,A.H.; Fadhil,A.M.A. ; and Hameed,M.A. (2014) .Immunohistochemical study  of Estrogen 
, Progesterone Receptor and Her-2neu Oncogene with Her-2neu Biomarker Estimation by ELISA 
Technique in Primary Breast Cancer before Chemical Therapy . Iraqi Journal of Science , Vol.55, 
No.1,pp:132-144.                                                                                                                         
(3)AL-Siagh,T.H.T. ; AL-Bayati, S.A. ; and Ahmed,F.A. (2012). Evaluation of CA15-3,Her-2/neu and 
estrogen/progesterone status in breast cancer patients treatedby surgical removal and chemotherapy. 
Iraqi J.Pharm.,Vol.12,No.1,pp:1-7.                       
(4)Hana,D.B. (2010) . Association of Interleukin 6 with positive Immunohistochemical staining of Estrogen 
Receptor in Breast Cancer Pattients . AJPS, Vol.7, No.1,pp:106-114.                                                                                                  
(5)Hayashi,S.I.; Eguchi,H.;Tanimoto,K.;Yoshida,T.; Omoto,Y.;Inoue,A.;Yosida,N.;and Yamaguchi,Y. 
(2003).The expression and function of estrogen receptor α andβ inhuman breast cancerand its clinical 
application. Endocrine-Related Cancer, Vol.(10),pp:193-202.                                                                                                                  
 gro.etsii.www                                                                                                 ygolonhceT dna ecneicS efiL ni secnavdA




 rotpecer negortse mureS .)4102(.P.W,hoK dna;.L.E,gnuoY;.M.J,nauY.A,niJ;.Y,gnoG;.J,iL;.W.V,miL)6(
 ,2.oN ,12.loV , recnaC taleR .rcodnE . nemow lasuaponemtsop gnoma ksir recnac tsaerb dna ytivitcaoib
                                                .372-362:pp
 enoretsegorp dna negortse fo sisylana lacimehcotsihonummI . )1102( .H.A,deejaM dna .S.A, deeaS)7(
                                                                                                   .83-43:pp,)1(32.loV,yrtsitneD egelloC.hgaB.J .snoisel lavignig ni noisserpxe srotpecer
 noisreV lacitsitatS.ediuG sꞌresU , metsyS sisylanA lacitsitatS.)2102(.SAS)8(
                                                                                           .ASU.C.N.yraC.cnI,.snI.SAS.deht1.9
 dna negortse rof ASILE owt fo tnempoleveD.)1002(.T.J,uW dna;.C.K,oosT;.L.T,uW;.F.C,nuS)9(
 ,.lanA.baL.nilC.J.yspoib eroc dna etaripsa eldeen enif rof ytivitisnes tneiciffus htiw rotpecer enoretsegorp
                                              .341-831:pp:)3(51
 
 
 دراسة علاقة الارتباط مابين المستقبلات الهرمونية في المريضات العراقيات المصابات بمرض سرطان الثدي
 د.ندى عبد الصاحب العلوان*   د.عالية اسماعيل ابراهيم*   د.علياء سعدون عبد الرزاق**
 * المركز الوطني الريادي لبحوث السرطان / جامعة بغداد
  المستهلك / جامعة بغداد ** مركز بحوث السوق وحماية
 moc.oohay@nodas.aila
 الخلاصة
ت سرطان الثدي يعتبر أحد انواع السرطان شيوعاً في العالم كما يعتبر احد اهم اسباب الوفاة بين النساء العراقيات . إن لاكتشاف مستقبلا   
توقع فترة العيش بعد العلاج والى امكانية رجوع الورم مرة الهرمونات )الاستروجين والبروجستيرون( أثر كبير في اختيار المريضات للعلاج و
يقوم البحث على اساس قياس نسبة أخرى ويعود سبب ذلك الى العلاقة بين درجة الورم ونسبة تمثيل مستقبلات الهرمونات على سطح الخلايا . 
كلينيكية في النساء العراقيات المصابات بسرطان الثدي . في النسيج ومصل الدم وملاحظة العلاقة بين مستوى المستقبلات والحالة الا  RE و   RP
( سنة 86- 82في مستشفى الاورام التعليمي وتم اختيار المصابات من الفئة العمرية ) 4102الى كانون الاول  4102تم بدأ الدراسة من مايس 
% وان نسبة 5,26ديهن تاريخ عائلي مرضي هي في النسيج ومصل الدم وأظهرت النتائج ان نسبة اللواتي ل  RE و   RPحيث قيست لهن نسبة 
% 01وان نسبة الدرجة الاولى هي % 3,31% اما الدرجة الثالثة فكانت بنسبة 7,67المريضات اللواتي لديهن الورم من الدرجة الثانية هي 
ن حساسية وخصوصية الدراسة في تقنية الاليزا والدراسة النسيجية المناعية وا  RE و   RPوان ليس هنالك فروق معنوية في قياس نسبة 
% 96( نغم/مل و 0,1% )07للدراسة النسيجية هي   RE و   RPالنسيجية المناعية هي افضل من تقنية الاليزا حيث كانت حساسية وخصوصية 
  ( نغم/مل على التوالي . 59,0% )03( نغم/مل و 9,0% )83( نغم/مل على التوالي اما في تقنية الاليزا فهي 0,1)
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